Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOB015B in Pediatric Distal Subungual Onychomycosis
2024-513214-34-00Phase 2Authorised
- Sponsor
- Moberg Pharma AB
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of Terclara in Distal Lateral Subungual Onychomycosis (DLSO), sponsored by Moberg Pharma AB. Primary endpoint: Treatment success at Week 48. Planned start Jul 2024; status: authorised.
02
Drugs
Terclara
03
Conditions
Distal Lateral Subungual Onychomycosis (DLSO)
Beyond the preview
Go deeper on 2024-513214-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513214-34-00.